Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: www.goldcopd.orgAccessed December 21, 2016
   Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med2005143531732616144890
   PubMed Web of Science ®Google Scholar
• DusserDBravoMLIaconoPThe effect of tiotropium on exacerbations and airflow in patients with COPDEur Respir J200627354755516507855
   PubMed Web of Science ®Google Scholar
• HalpinDMenjogeSVielKPatient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisationsPrim Care Respir J200918210611319407916
   PubMedGoogle Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomized controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy vs inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy vs long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, random-ized controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 vs placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• ArievichHOverendTRenardDA novel model-based approach for dose determination of glycopyrronium bromide in COPDBMC Pulm Med20121217423217058
   PubMed Web of Science ®Google Scholar
• RennardSFogartyCReisnerCRandomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary diseaseBMC Pulm Med20141411825027304
   PubMed Web of Science ®Google Scholar
• LeakerBRBarnesPJJonesCRTutuncuASinghDEfficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary diseaseBr J Clin Pharmacol201579349250025243340
   PubMed Web of Science ®Google Scholar
• SinghDRaviAReidFBuckHO’ConnorGDownGBroncho-dilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomized crossover studyPulm Pharmacol Ther20163791426827913
   PubMed Web of Science ®Google Scholar
• RabeKFTimmerWSagkriotisAVielKComparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPDChest2008134225526218403672
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDINTRUST-1 and INTRUST-2 study investigatorsConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 vs single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination vs mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol vs tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomized controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomized studyBMC Pulm Med201414117825404569
   PubMed Web of Science ®Google Scholar
• TashkinDPVargheseSTCombined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or genderPulm Pharmacol Ther201124114715220659577
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat(®) and tiotropium Handi-Haler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• JungKSParkHYParkSYComparison of tiotropium plus fluti-casone propionate/salmeterol with tiotropium in COPD: a randomized controlled studyRespir Med2012106338238921975275
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide vs individual components in moderate to severe COPDThorax200863759259818245142
   PubMed Web of Science ®Google Scholar
• ChatterjeeAShahMD’SouzaAOBechtelBCraterGDalalAAObservational study on the impact of initiating tiotropium alone vs tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary diseaseRespir Res2012131522340019
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• ScichiloneNBenfanteAMorandiLBelliniFPapiAImpact of extrafine formulations of inhaled combinations on patient-related outcomes in asthma and COPDPatient Relat Outcome Meas2014515316225473323
   PubMedGoogle Scholar
• SørheimICJohannessenAGulsvikABakkePSSilvermanEKDemeoDLGender differences in COPD: are women more susceptible to smoking effects than men?Thorax201065648048520522842
   PubMed Web of Science ®Google Scholar
• AryalSDiaz-GuzmanEManninoDMInfluence of sex on chronic obstructive pulmonary disease risk and treatment outcomesInt J Chron Obstruct Pulmon Dis201491145115425342899
   PubMed Web of Science ®Google Scholar
• JainNKThakkarMSJainNRohanKASharmaMChronic obstructive pulmonary disease: Does gender really matter?Lung India201128425826222084538
   PubMedGoogle Scholar
• VestboJSorianoJBAndersonJACalverleyPPauwelsRJonesPGender does not influence the response to the combination of salme-terol and fluticasone propionate in COPDRespir Med200498111045105015526804
   PubMed Web of Science ®Google Scholar
• TashkinDCelliBKestenSLystigTDecramerMEffect of tiotro-pium in men and women with COPD: Results of the 4-year UPLIFT® trialRespir Med2010104101495150420418083
   PubMed Web of Science ®Google Scholar
• DumitrasSSechaudRDrollmannAEffect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrroniumInt J Clin Pharmacol Ther2013511077177924040847
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• WangCSunTHuangYEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J Chron Obstruct Pulmon Dis201510576825609940
   PubMed Web of Science ®Google Scholar
• SinghDSchröder-BaboWCohuetGThe bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: a randomized crossover study (the TRIDENT study)Respir Med2016114849027109816
   PubMed Web of Science ®Google Scholar